REUTERS - Shares in Wockhardt fell by their daily limit of 5 percent on Monday after Britain's drug regulator revoked its good manufacturing practice certificate for one of the Indian drugmaker's production facilities.
The Medicines and Healthcare Products Regulatory Agency will instead issue a restricted certificate, meaning Wockhardt will only be able to supply only "critical" products from the facility, the company said in a statement at the weekend.
Wockhardt earns about 12 million pounds in UK and European Union sales from the Chikalthana, Aurangabad facility, located in western India.
A number of top Indian generic drugmakers have faced compliance issues in recent years, with most complaints triggered by investigations by the U.S. Food and Drug Administration. (Reporting by Aradhana Aravindan; Editing by Edwina Gibbs)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app